Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.50 |
| ▸ | NQO2 | P16083 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505917 | 0.86 | MAPT (0.44) | MTNR1AMTNR1BNQO2NPC1RAB9A | |
| SCHEMBL3403700 | 0.86 | KMT2A (0.51) | MTNR1AMTNR1BNQO2NPC1RAB9A | |
| SCHEMBL14374385 | 0.82 | NPSR1 (0.52) | RAB9ALMNAACHE | |
| SCHEMBL14374386 | 0.79 | ACHE (0.48) | SMN1; SMN2HSD17B10ACHE | |
| SCHEMBL10050932 | 0.77 | MPO (0.54) | MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11659554 | 0.75 | MTNR1A (0.48) | MTNR1AMTNR1BNQO2ALDH1A1MAPT | |
| SCHEMBL31465075 | 0.74 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL5042357 | 0.74 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL7784332 | 0.74 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2SMN1; SMN2 | |
| SCHEMBL7820683 | 0.72 | NQO2 (0.61) | MTNR1AMTNR1BNQO2SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884243-B2 | reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide | ZACH SYSTEM (FR) | 2011-02-08 | — | — | US | claimed |
| EP-1716097-B1 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | ZACH SYSTEM (FR) | 2010-10-13 | — | — | EP | claimed |
| EP-1897868-A1 | N-(3H-inden-1-yl)-acetamide compounds | PPG-Sipsy (FR) | 2008-03-12 | — | — | EP | claimed |
| US-7884243-B2 | reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide | ZACH SYSTEM (FR) | 2011-02-08 | — | — | US | disclosed |
| US-7884243-B2 | reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide | ZACH SYSTEM (FR) | 2011-02-08 | — | — | US | disclosed |
| US-7884243-B2 | reacting 3,4-dihydo-1H-naphtalen-2-one oxime with acetic anhydride in tetrahydrofuran solvent using heterogenous catalyst ( Rh or Ir on Carbon support) in presence of hydrogen to perform hydrogenation/isomerization to form N-(3,4-Dihydro-naphthalen-2-yl)-acetamide | ZACH SYSTEM (FR) | 2011-02-08 | — | — | US | disclosed |
| EP-1716097-B1 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | ZACH SYSTEM (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-1716097-B1 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | ZACH SYSTEM (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-1720823-B1 | NEW PROCESS FOR THE SYNTHESIS OF SUBSTITUTED ALPHA-AMINOIDAN DERIVATIVES | ZACH SYSTEM (FR) | 2009-08-26 | — | — | EP | disclosed |
| US-7456320-B2 | Process for the synthesis of substituted alpha-aminoindan derivatives | ZACH SYSTEM (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1897868-A1 | N-(3H-inden-1-yl)-acetamide compounds | PPG-Sipsy (FR) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897868-A1 | N-(3H-inden-1-yl)-acetamide compounds | PPG-Sipsy (FR) | 2008-03-12 | — | — | EP | disclosed |
| US-20070191640-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | PPG-SIPSY (FR) | 2007-08-16 | — | — | US | disclosed |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | PPG-SIPSY (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | PPG-SIPSY (FR) | 2007-06-07 | — | — | US | disclosed |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | PPG-SIPSY (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1720823-A1 | NEW PROCESS FOR THE SYNTHESIS OF SUBSTITUTED ALPHA-AMINOIDAN DERIVATIVES | PPG-Sipsy (FR) | 2006-11-15 | — | — | EP | disclosed |
| EP-1574498-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | PPG-Sipsy (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005082838-A1 | NEW PROCESS FOR THE SYNTHESIS OF SUBSTITUTED ALPHA -AMINOINDAN DERIVATIVES | PPG-SIPSY (FR) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191640-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | ALDH7A1, ALAD, ASPH | MTNR1A 2294/4885MTNR1B 3422/4885NQO2 97/4885 |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | CBR3, CBR1, CYB5R3 | MTNR1A 529/4885MTNR1B 1001/4885NQO2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.